173 related articles for article (PubMed ID: 38118368)
21. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study.
Shah MA; Kojima T; Hochhauser D; Enzinger P; Raimbourg J; Hollebecque A; Lordick F; Kim SB; Tajika M; Kim HT; Lockhart AC; Arkenau HT; El-Hajbi F; Gupta M; Pfeiffer P; Liu Q; Lunceford J; Kang SP; Bhagia P; Kato K
JAMA Oncol; 2019 Apr; 5(4):546-550. PubMed ID: 30570649
[TBL] [Abstract][Full Text] [Related]
22. First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis.
Zheng Z; Chen H; Cai H; Zhu H
Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):397-404. PubMed ID: 38031985
[TBL] [Abstract][Full Text] [Related]
23. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis.
Zhu X; Shanzhou Q; Li D; Pang X; Ma D
BMC Cancer; 2021 Nov; 21(1):1195. PubMed ID: 34758782
[TBL] [Abstract][Full Text] [Related]
24. Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study.
He W; Wang C; Wu L; Wan G; Li B; Han Y; Li H; Leng X; Du K; Chen H; Wang Q; Peng L
Front Immunol; 2022; 13():853922. PubMed ID: 35720312
[TBL] [Abstract][Full Text] [Related]
25. Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial.
Zhou C; Huang D; Fan Y; Yu X; Liu Y; Shu Y; Ma Z; Wang Z; Cheng Y; Wang J; Hu S; Liu Z; Poddubskaya E; Disel U; Akopov A; Dvorkin M; Zheng W; Ma Y; Wang Y; Li S; Yu C; Rivalland G
J Thorac Oncol; 2023 Jan; 18(1):93-105. PubMed ID: 36184068
[TBL] [Abstract][Full Text] [Related]
26. Benefit-Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- and Platinum-Based Chemotherapy.
Pelosof L; Saung MT; Donoghue M; Casak S; Mushti S; Cheng J; Jiang X; Liu J; Zhao H; Khazraee M; Goldberg KB; Theoret M; Lemery S; Pazdur R; Fashoyin-Aje L
Oncologist; 2021 Apr; 26(4):318-324. PubMed ID: 33345396
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of PD-1 inhibitors as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China: an economic evaluation based on network meta-analysis.
Liu S; Zhao L; Shi F; Kuai L; Liu R; Tang J
Int J Clin Pharm; 2024 Jun; 46(3):675-683. PubMed ID: 38407692
[TBL] [Abstract][Full Text] [Related]
28. The effects of tislelizumab treatment on the health-related quality of life of patients with advanced non-small cell lung cancer.
Huang D; Zhou C; Barnes G; Ma Y; Li S; Zhan L; Tang B
Cancer Med; 2023 Aug; 12(16):17403-17412. PubMed ID: 37587845
[TBL] [Abstract][Full Text] [Related]
29. Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Lu S; Lou Y; Rong Y; Huang Z; Lin X; Chen J; Luo K
Clin Drug Investig; 2023 Aug; 43(8):643-652. PubMed ID: 37542611
[TBL] [Abstract][Full Text] [Related]
30. Circulating tumor DNA serial monitoring of relapse and responses to tislelizumab immunotherapy as second‑line monotherapy for metastatic esophageal squamous cell carcinoma: A prospective study.
He Q; Shi X; Yan J; Wu M; Gu C; Yu X
Mol Clin Oncol; 2024 Apr; 20(4):29. PubMed ID: 38414510
[TBL] [Abstract][Full Text] [Related]
31. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial.
Qin S; Kudo M; Meyer T; Bai Y; Guo Y; Meng Z; Satoh T; Marino D; Assenat E; Li S; Chen Y; Boisserie F; Abdrashitov R; Finn RS; Vogel A; Zhu AX
JAMA Oncol; 2023 Dec; 9(12):1651-1659. PubMed ID: 37796513
[TBL] [Abstract][Full Text] [Related]
32. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
33. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE).
Yan X; Duan H; Ni Y; Zhou Y; Wang X; Qi H; Gong L; Liu H; Tian F; Lu Q; Sun J; Yang E; Zhong D; Wang T; Huang L; Wang J; Chaoyang Wang ; Wang Y; Wan Z; Lei J; Zhao J; Jiang T
Int J Surg; 2022 Jul; 103():106680. PubMed ID: 35595021
[TBL] [Abstract][Full Text] [Related]
34. First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study.
Li J; Chen Z; Bai Y; Liu B; Li Q; Zhang J; Zhou J; Deng T; Zhou F; Gao S; Yang S; Ye F; Chen L; Bai W; Yin X; Cang S; Liu L; Pan Y; Luo H; Ji Y; Zhang Z; Wang J; Yang Q; Li N; Huang R; Qu C; Ni J; Wang B; Xu Y; Hu J; Shi Q; Yang J
Nat Med; 2024 Mar; 30(3):740-748. PubMed ID: 38302715
[TBL] [Abstract][Full Text] [Related]
35. Effects of sintilimab plus chemotherapy as first-line treatment on health-related quality of life in patients with advanced esophageal squamous cell carcinoma: results from the randomized phase 3 ORIENT-15 study.
Lu Z; Kong L; Wang B; Wang J; Liu L; Shu Y; Yang L; Sun G; Cao G; Ji Y; Cui T; Liu H; Qiu W; Li N; Li G; Luo H; Hou X; Zhang Y; Yue W; Xue L; Liu Z; Pan Y; Gao S; Wang X; Pan Z; Zhang S; Lin G; Xie Y; Gu K; Ren T; Li W; Li T; Wang S; He W; Fan Y; Liang J; Xia B; Zhao L; Wang S; Shen L
EClinicalMedicine; 2024 Jun; 72():102623. PubMed ID: 38800802
[TBL] [Abstract][Full Text] [Related]
36. The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysis.
Gao J; Song Y; Kou X; Tan Z; Zhang S; Sun M; Zhou J; Fan M; Zhang M; Song Y; Li S; Yuan Y; Zhuang W; Zhang J; Zhang L; Jiang H; Gu K; Ye H; Ke Y; Qi X; Wang Q; Zhu J; Huang J
Cancer Med; 2024 May; 13(10):e7203. PubMed ID: 38769930
[TBL] [Abstract][Full Text] [Related]
37. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).
Kato K; Doki Y; Ogata T; Motoyama S; Kawakami H; Ueno M; Kojima T; Shirakawa Y; Okada M; Ishihara R; Kubota Y; Amaya-Chanaga C; Chen T; Matsumura Y; Kitagawa Y
Esophagus; 2023 Apr; 20(2):291-301. PubMed ID: 36401133
[TBL] [Abstract][Full Text] [Related]
38. First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590.
Kojima T; Hara H; Tsuji A; Yasui H; Muro K; Satoh T; Ogata T; Ishihara R; Goto M; Baba H; Nishina T; Han S; Sakata T; Yatsuzuka N; Doi T; Kato K
Esophagus; 2022 Oct; 19(4):683-692. PubMed ID: 35668304
[TBL] [Abstract][Full Text] [Related]
39. Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
Shi F; He Z; Su H; Wang L; Han S
Front Pharmacol; 2022; 13():961347. PubMed ID: 36467065
[No Abstract] [Full Text] [Related]
40. Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic esophageal squamous cell carcinoma trial: a prospective single-arm, phase II study (PILOT trial).
Ding C; Guo Y; Zhou Y; He Y; Chen C; Zhang M; Guo X
BMC Cancer; 2023 Dec; 23(1):1237. PubMed ID: 38102553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
